LEAN Project: Weight Loss and Appetite Suppression

The Cooper Institute60 enrolled

Overview

The primary aim is to examine whether the intake of PhosphoLEAN is effective in aiding a cohort of women in losing weight. Participants taking the supplement will have significantly greater improvement in study outcomes than those taking the placebo.

Participants will be randomized to either a control or treatment group taking the dietary supplement containing a soy lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and caffeine free Green Tea-derived epigallocathchin gallate (EGCG) whose trade name is PhosphoLean. The outcome is to determine the effects on indices of weight loss and appetite suppression. Participants will return at 6, 12, and 16 weeks for clinical measures.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Weight Loss

Interventions

PhosphoLeanDRUG

Eligibility

Sex: FEMALEMin age: 30 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 30-45 years, women, overweight or obese class I, premenopausal, maintain current diet and exercise regimen Exclusion Criteria: * pregnant or planning to become pregnant, currently have or history of cancer, heart disease, anemia, diabetes, depression

Locations (1)

The Cooper Institute

Dallas, Texas, United States

Outcomes

Primary Outcomes

Weight Loss

Appetite Suppression

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.